The role of telomerase reverse transcriptase (TERT) promoter mutations in prognosis in bladder cancer

Song Wan, Xuan Liu, Wei Hua, Ming Xi, Yulin Zhou, and Yueping Wan
Department of Urology, Huadu District People’s Hospital of Guangzhou, Guangzhou, China

ABSTRACT
Telomerase reverse transcriptase (TERT) promoter mutations have been recognized as a common genetic event in bladder cancer (BC). Many studies have found the high TERT promoter mutations’ prevalence in BC recurrence patients which may make the TERT promoter mutations become a potential prognosis prediction of BC. We performed a systematic search in Embase, PubMed, and Web of Science in January 2021. The aspects of evaluation, methods, validation, and results were used to evaluate the included studies’ quality. We reviewed two of the most common mutations in types of TC, C288T and C250T and their relationship with prognosis of BC. Eight studies contained 1382 cases were enrolled in our study. The percentage of TERT promoter mutations in these cases was 62.5%. A statistically significant association was detected between TERT promoter mutation and recurrence (HR: 2.03, 95% CI: 1.53–2.68, p < 0.001). However, TERT promoter mutation was not significant associated with overall survival (HR: 1.077, 95% CI: 0.674–1.718, p = 0.757). No significant heterogeneities were observed (I^2 = 47.5%, P = 0.064; I^2 = 58.7%, p = 0.120, respectively). Bladder cancer patients with TERT promoter mutations take a higher risk of recurrence. TERT promoter mutations may become a potential prediction factor for bladder cancer recurrence.

CONTACT Yueping Wan wanyueping1958@163.com Department of Urology, Huadu District People’s Hospital of Guangzhou, Guangzhou 510800, China

ARTICLE HISTORY
Received 22 February 2021
Revised 7 April 2021
Accepted 7 April 2021

KEYWORDS
Bladder cancer; tert promoter mutations; prognosis
Introduction

Telomeres are a kind of nucleoprotein complexes composed of many short non-transcribed DNA sequences, TTAGGG, proteins [1]. They are responsible for protecting the ends of chromosomes from being shorter as cells divide by reducing DNA sequences. Telomeres get shorter when cells divide. When the telomere length is short at a particular level, this cell will come to an end. Telomerase is a type of enzyme that can take telomere DNA TTAGGG into the end of chromosome to shorten telomere [2]. It is composed of telomerase reverse transcriptase (hTERT), telomerase RNA component (TERT), and telomerase associated protein 1 (htp1) [3]. Telomerase RNA component (TERC) plays a role as replication template, while TERT catalyzes the addition of DNA fragment TTAGGG [4]. Telomerase activity is low expressed in most normal and benign tumor tissues, but highly expressed in malignant tumors, which is associated with the ability of persistent division of malignant tumor cells [5]. Therefore, TERT mutation has been a crucial research hot-spot in the pathogenesis of tumor since 2013 when it was firstly reported [6]. TERT gene locates in chromosome 5 and has 16 exons and 15 introns, with a total length of 35 KB [4]. The crucial promoter of TERT, located 330 bp in front of the translation initiation site, is one of the most commonly described mutation sites in studies. TERT promoter mutations mainly appeared in two hot spots (c250t and c228t) of 1,295,250 c > T and 12,952,228 c > T [5]. These two mutations are associated with the ATG (initiation codon) and the aggressiveness of tumors. Therefore, we hypothesized that TERT promoter mutation was associated with bladder cancer recurrence. We performed a meta-analysis to examine and summarize all data on TERT promoter mutations in bladder cancer and verified the above hypothesis.

Methods

Search strategy

This meta-analysis was performed according to PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [7]. We finished the search in Embase, Web of Science, and PubMed (MEDLINE) up to January 2021, and finally included 10 studies. We included all studies for a total of 1382 cases. The filtering process is shown in Figure 1. The search contains the following keywords: ‘bladder cancer’, ‘urothelial cancer’, ‘TERT’, ‘C228T’, ‘C250T’, and

Figure 1. Schematic flow diagram for selection of included studies.
‘prognosis’. All studies were published in English.
To identify all possible eligible studies, a manual
search was conducted on references cited from
each original study.

Inclusion and exclusion criteria
Qualified studies should meet the following
inclusion criteria: (1) definite diagnosis of blad-
cancer by pathology, (2) without other pre-
vious cancer history, (3) reporting the
relationship between TERT promoter mutation
and recurrence-free survival (RFS) and/or overall
survival (OS), (4) full-text studies containing
sufficient and available data for calculating
hazard ratios (HRs) and its ninety-five percent
confidence intervals (CIs), (6) related clinicopat-
holological data were available. The exclusion
criteria were listed in the following: (1) unre-
related topics or other types of articles, such as
abstracts and reviews; (2) without data on asso-
ciations between TERT promoter mutation
and BC; and (3) data were collected only from
studies of animal models or cell lines. The major
determinants of recurrence are clinicopatholog-
ical features according to the European
Association of Urology [8].

Data extraction and quality assessment
We collected the following data from the
included study: 1, author’s name, year of pub-
llication; 2, number of patients; 3, number and
percentage of mutation; 4, HR and 95% CI. The
Cochrane Prognostic Studies group [9] was mea-
sured to assess the methodological quality in
Rezman 5 (Cochrane Library Software, Oxford, UK).

### Table 1. Characteristics of the included studies.

| Study           | Year | No. of patients | Percentage of mutation | Mutation point | Type of bladder cancer | Follow up time | Sample types |
|-----------------|------|-----------------|------------------------|----------------|------------------------|----------------|--------------|
| Roggisch, J [19]| 2020 | 75              | 63 (84.0%)             | C288T&C250T    | urothelial             | 53             | tissue       |
| Hayashi, Y [17] | 2020 | 54              | 16 (29.6%)             | C288T&C250T    | urothelial             | 60             | tissue       |
| Yujio, H [16]   | 2020 | 35              | 6 (17.4%)              | C288T&C250T    | urothelial             | 72             | urine        |
| Batista, R [13] | 2020 | 125             | 70 (56.0%)             | C288T&C250T    | urothelial             | 150            | tissue       |
| Leao, R [18]    | 2019 | 237             | 182 (76.8%)            | not mentioned  | urothelial             | 200            | tissue       |
| Descotes, F [15]| 2017 | 348             | 280 (80.5%)            | C288T&C250T    | urothelial             | 60             | urine        |
| Critelli, R [14]| 2016 | 229             | 119 (52.0%)            | C288T&C250T    | urothelial             | 96             | urine        |
| Rachakonda, P [6]| 2013 | 279             | 186 (66.7%)            | C288T&C250T    | urothelial             | 180            | tissue       |

Statistical analyses
Stata software (Stata Corporation, College Station,
version 12.0, TX, USA) carried out the analysis.
The relationship between TERT promoter mutations
and BC prognosis was tested by calculating
hazard ratios (HRs) and its ninety-five percent CIs
and analyzing survival data’s quantitative aggrega-
tion. When survival data were presented only in
Kaplan Meier curves, the methods of Williamson
[10], Parmar [11], and Tierney [12] for extracting
HRs with 95.0% CIs were applied. Chi-squared
tests and I² statistics were performed to test the
existing heterogeneity of the enrolled studies.
Statistically significant differences in heterogeneity
existed when P < 0.05 and I² > 50.0%. Fixed-effects
or random-effects models were performed to test
the pooled HRs. To assess publication bias, the
symmetry of funnel plots was evaluated visually;
meanwhile, Egger’s and Begg’s tests were formally
performed. When the visual asymmetry of funnel
plots was found with P < 0.05, publication bias
existed. Sensitivity analysis was carried out for
evaluating the stability and reliability of the meta-
analysis.

Results
Relevant literature was collected as planned, and
then evaluated and analyzed the relationship
between TERT promoter mutation and the recur-
rence of bladder cancer.

Literature search and study qualities
Literature retrieval initially found 109 records, and
25 candidate studies were selected (Figure 1). After
screening the full texts, 15 articles were excluded
because there was no way to extract survival data
from them. Ultimately, eight eligible studies [6,13–
with available survival data were enrolled in this study. The main information and characteristics of the included studies are listed in Table 1. The enrolled studies, published between 2013 and 2020, were all conducted in patients with bladder cancer. One thousand three hundred and eighty-two cases with BC were enrolled in this study. The sample sizes for OS and RFS were 354 and 1382, respectively. One study did not mention mutation points [18] and the other one did not mention the follow-up time [20]. Figure 2 exhibits that the methodologic quality assessment of the enrolled studies was all good quality.

**Association of TERT promoter mutations with recurrence of BC**

Eight studies [6,13–19] provided available data of recurrence in both mutation-positive and mutation-negative groups (heterogeneity: $I^2 = 47.5\%, \ p = 0.064$). Using pooled data, the results showed that TERT promoter mutation positive patients were more likely to relapse bladder cancer according to the meta-analysis (HR: 2.03, 95% CI: 1.53–2.68, $p < 0.001$, Figure 3a). In case number subgroup, the HR was 1.84 (95% CI, 1.25–2.71, $p = 0.002$) in less than 100

---

**Figure 2.** Methodological quality of the retrospective studies.
case subgroup and 2.13 (95% CI, 1.53–2.68, p < 0.001) in nonrandom subgroup, respectively. Three studies [14–16] examined TERT promoter mutations in urine, and five studies [6,13,17–19] examined TERT promoter mutations in bladder tissues. In specimen’s subgroup analysis, the HR was 2.03 (95% CI, 1.53–2.68, p < 0.001) in urine subgroup and 1.83 (95% CI, 1.33–2.51, p < 0.001) in tissue subgroup. Subgroup analysis results are exhibited in Figure 5 and Figure 6.

Association of TERT promoter mutations with overall survival of BC

Two studies [6,19] provided available data on overall survival in the TERT mutation-positive and TERT mutation-negative group (heterogeneity: $I^2 = 58.7\%$, $p = 0.120$). Both studies examined the mutation in tissues. In the pooled data, the results showed that patients with mutations took a higher risk of relapsed bladder cancer according to the meta-analysis (HR: 1.077, 95% CI: 0.674–1.718, p = 0.757, Figure 3b).

**Figure 3.** Forest plot of the HR analysis of TERT promoter mutation with RFS and OS of BC. A forest plot of RFS; B forest plot of OS.
Publication bias and sensitivity analysis

Egger’s test and Begg’s funnel plot were performed to evaluate the potential publication bias of enrolled studies in this meta-analysis. Significant publication bias was not detected for RFS groups (symmetrical shape of funnel plots and Begg’s test: P = 0.536, Egger’s test: P = 0.413, Figure 4a) or OS groups (symmetrical shape of funnel plots, Figure 4c). Testing the impact of each study on both RFS groups and OS groups’ pooled HR, and verify the results’ robustness, we performed sensitivity analysis by removing single study in sequence and obtained pooled HR for the remaining studies simultaneously. Sensitivity analysis showed that the influence of pooled HR was not significant when excluding any single study, which suggested that the results were relatively robust (Figure 4b, Figure 4d).

Discussion

Bladder cancer is the sixth most prevalent cancer in the world, which the incidence rate has been increasing in recent years [21]. The increase in incidence rate, and the high cost of monitoring every patient, has brought a heavy burden to the public health system [22]. Prompt treatment, including complete transurethral resection, can make the five-year-long survival rate more than 90%. However, as high as 70–80% of the relapses make recurrence a major challenge for clinical management [23]. TERT promoter mutations were occurred in 30% to 84% of BC cases [6,13–20,24]. These results indicate that TERT promoter mutations are very frequent genomic events reported in BC. TERT promoter mutations can be helpful for early detection of recurrence and better adaptation to follow-up frequency and treatment. Many studies have reported that TERT
promoter mutations were related to recurrence in various malignancies [25–28]. However, the potential of TERT promoter mutations’ prediction value in BC is still controversial. For example, Batista et al. [13] indicated that TERT promoter mutations did not significantly relate to recurrence of BC (HR: 1.352, 95% CI: 0.703–2.600, p = 0.367). Until now, no meta-analysis has been conducted
to describe the prognostic value of TERT promoter mutations in BC patients. We produced this meta-analysis of eight studies including 1382 cases, to describe the prognostic value of TERT promoter mutations for recurrence in BC patients. This is the first meta-analysis to explore whether TERT promoter mutations made patients’ prognosis worse.

We found that the TERT promoter mutations were related to BC recurrence. The presence of mutations was not related to OS of BC. Mutations of the TERT promoter in BC resulted in increased TERT mRNA levels and increased tumor invasiveness [29]. The results were consistent with urine and tissue specimens. Many studies have shown that TERT promoter mutations significantly decreased RFS [15,18] and OS [24,30]. However, there were also contradictory ideas in this area. Allory [29] showed that OS was not associated with TERT promoter mutations. In contrast, there were studies of other tumors in which TERT promoter mutations were related to higher grade and reduced survival [31,32]. However, in order to predict the survival of patients with BC, it is necessary to find more than one biomarker.

The intertumoral molecular heterogeneity of BC made it hard to identify prognostics and biomarkers and targets for treatment or chemotherapy. The high frequency of occurrence of mutation made TERT the most common mutated gene in UBC. Therefore, it became a potential therapeutic target. Studies using strategies of telomerase inhibition have shown that strong TERT inhibition can result in progressive telomere shortening and ultimately to cancer cell apoptosis, including using of small-molecule inhibitors [33], immunotherapy [34] and antisense oligonucleotides [35]. At present, many anti-telomerase therapies are evaluated in clinical trials for many types of cancer, and brings hope for future treatment.

The limitations of this study were listed in the following. Firstly, all the enrolled studies were published in English, which may lead to publication bias. Second, the approaches for assessment of TERT promoter mutation were lack of uniform standard which might influence the results. Some studies received clinical samples from urine cytology, while others got from bladder biopsy. Furthermore, some data extracted from KM survival curves of included studies may be less reliable than data obtained directly. Lastly, many studies did not provide recurrence data of different types of mutations, respectively.

Conclusion

Bladder cancer patients with TERT promoter mutations take a higher risk of recurrence. How these mutations affect the occurrence or development of bladder cancer has not been found. TERT promoter mutations may become a potential prediction factor for recurrence and a potential therapeutic target.

Highlights:

(1) Telomerase reverse transcriptase (TERT) promoter mutations are common genetic event in bladder cancer.
(2) TERT promoter mutations can be detected in both tissue and urine.
(3) TERT promoter mutations can predict the recurrence of bladder cancer.

Acknowledgements

We would like to thank the researchers and study participants for their contributions.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
All data analyzed and presented in this study are available from the corresponding author on reasonable request.

Disclosure statement

No potential conflict of interest was reported by the author(s).

ORCID

Yueping Wan  http://orcid.org/0000-0002-1025-9222

References

[1] Günes C, Rudolph KL. The role of telomeres in stem cells and cancer. Cell. 2013;152(3):390–393.
[2] Kyo S, Takakura M, Fujiwara T, et al. Understanding and exploiting hTERT promoter regulation for
[3] Popli DB, Sircar K, Chowdhry A. Telomerase: an exploration toward the end of cancer. Indian J Dent Res Official Publication of Indian Soc Dental Res. 2017;28(5):574–584.

[4] Cong YS. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet. 1999;8(1):137–142.

[5] Vinagre J, Almeida A, Pópulo H, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4(1):2185.

[6] Rachakonda PS, Hosen I, De Verdier PJ, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA. 2013;110(43):17426–17431.

[7] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.

[8] Van Rhijn BWG, Hentschel AE, Bründl J, et al. Prognostic Value of the WHO1973 and WHO2004/2016 classification systems for grade in primary ta/t1 non-muscle-invasive bladder cancer: a multicenter European Association of urology non-muscle-invasive bladder cancer guidelines panel study. European Urology Oncology. 2021.

[9] Bouwmeester W, Zuithoff NP, Mallett S, et al. Reporting and methods in clinical prediction research: a systematic review. PLoS Med. 2012;9(5):1–12.

[10] Williamson PR, Smith CT, Hutton JL, et al. Aggregate data meta-analysis with time-to-event outcomes. Stat Med. 2002;21(22):3337–3351.

[11] Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–2834.

[12] Tierney JF, Stewart LA, Gersh K, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(1):16.

[13] Batista R, Lima L, Vinagre J, et al. TERT promoter mutation as a potential predictive biomarker in BCG-treated bladder cancer patients. Int J Mol Sci. 2020;21(3):3.

[14] Critelli R, Fasanelli F, Oderda M, et al. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up. Oncotarget. 2016;7(41):67435–67448.

[15] Descotes F, Kara N, Decaussin-Petrucci M, et al. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine. Br J Cancer. 2017;117(4):583–587.

[16] Hayashi Y, Fujita K, Matsuzaki K, et al. Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer. Front Oncol. 2020;10:755.

[17] Hayashi Y, Fujita K, Nojima S, et al. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer. Mol Oncol. 2020;14(10):2375–2383.

[18] Leão R, Lee D, Figueirêdo A, et al. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer. Int J Cancer. 2019;144(7):1676–1684.

[19] Röggisch J, Ecke T, Koch S. Molecular identification of telomerase reverse transcriptase (TERT) promoter mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer. Urol Oncol. 2020;38(3):77–89.

[20] Grootenhuis AJ, Dudek AM, Verhaegh GW, et al. Independent replication of published germline polymorphisms associated with urinary bladder cancer prognosis and treatment response. Bladder Cancer (Amsterdam Netherlands). 2016;2(1):77–89.

[21] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953.

[22] Van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430–442.

[23] Netto GJ. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol. 2011;9(1):41–51.

[24] Hosen I, Rachakonda PS, Heidenreich B, et al. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. Int J Cancer. 2015;137(7):1621–1629.

[25] Gour E. TERT mutations in urine could predict bladder cancer recurrence. Lancet Oncol. 2017;18(8):e443.

[26] Jin A, Xu J, Wang Y. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer. Medicine (Baltimore). 2018;97(29):e11548.

[27] Sk O, Ms C, Mh P, et al. TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma. Scand J Gastroenterol. 2020;55(12):1433–1440.

[28] Plateau P, Coyaud E, Laurent E, et al. TERT promoter mutation as an independent prognostic marker for poor prognosis MAPK inhibitors-treated melanoma. Cancers (Basel). 2020;12(8):8.

[29] Allory Y, Beukers W, Sagrera A, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol. 2014;65(2):360–366.

[30] Russo IJ, Yu Y, Gordon NS, et al. Toward personalised liquid biopsies for urothelial carcinoma:
characterisation of ddPCR and urinary cfDNA for the detection of the TERT 228G>A/T mutation. Bladder Cancer (Amsterdam, Netherlands). 2018;4(1):41–48.

[31] Bournaud C, Descotes F, Decaussin-Petrucci M, et al. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma. Eur J Cancer (Oxford England 1990). 2019;108:41–49.

[32] Griewank KG, Murali R, Puig-Butille JA, et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst. 2014;106:9.

[33] Bryan C, Rice C, Hoffman H, et al. Structural basis of telomerase inhibition by the highly specific BIBR1532. Structure. 2015;23(10):1934–1942.

[34] Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev. 2013;39(5):444–456.

[35] Asai A, Oshima Y, Yamamoto Y, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 2003;63(14):3931–3939.